Igor Sherman

Igor Sherman is the CEO and Founder of Alpha Cancer Technologies Inc. since October 2008, focused on developing novel non-toxic therapies for cancer and autoimmune diseases globally. Sherman has served as a client at MaRS Innovation since 2010 and held the position of Director of Clinical Research and Scientific Affairs at YM BioSciences Inc. from September 2005 to December 2008, overseeing clinical development strategy and trial execution. Previous experience includes managing oncology trials in Canada as Scientific Director at AstraZeneca Canada from 2001 to 2003, and positions at Biovail as a Manager and Biovale Contract Research as a Manager from 2003 to 2004. Igor Sherman earned a Ph.D. in Biophysics and Biomedical Engineering from the University of Toronto and an M.Sc. in Physics of Living Systems from the Moscow Institute of Physics and Technology.